ArticleOphthalmology and therapy2026
Beyond Cost: Faricimab as a Driver of Service Efficiency and Quality in Neovascular Age-Related Macular Degeneration Care.
Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNeovascular age-related macular degeneration (nAMD) is a chronic, vision-threatening condition requiring ongoing anti-vascular endothelial growth factor (anti-VEGF) injections. As the population ages and the demand for eye care rises, capacity-constrained healthcare systems struggle to deliver timely treatment. In the UK, many patients experience delays, increasing the risk of irreversible visual loss. Therapies with extended dosing intervals, such as faricimab, may reduce treatment burden and improve care quality.
methodsA microsimulation model was developed representing a hypothetical UK National Health Service (NHS) retinal clinic over 5 years, comparing service and cost outcomes for two nAMD therapies. The study included a pairwise comparison (base case) of faricimab versus biosimilar aflibercept 2 mg, and a future market analysis comparing contrasting payer strategies, 'treatment choice' (75% faricimab market share) versus 'strict biosimilar mandate' (75% biosimilar market share). Outcomes included quality care delivery metrics, service utilisation, NHS provider costs, and litigation costs. Sensitivity analyses were performed to explore uncertainty.
resultsAcross all scenarios, faricimab reduced injection frequency, clinic visits, and treatment delays compared with biosimilar aflibercept 2 mg. In the base case, faricimab reduced delayed visits by 97.4% (158 vs 6171) and improved the key quality care delivery metric of loading phase completion by 54.1 percentage points (95.8% vs 43.7%). Faricimab was also associated with lower acquisition costs, with additional savings arising from reduced service and litigation-related costs. In the future market analysis, a treatment choice policy resulted in improved operational and quality-of-care metrics compared with a strict biosimilar mandate, resulting in lower total costs.
conclusionIn capacity-constrained settings, more durable options like faricimab can unlock operational capacity, enabling health systems to treat more patients, reduce delays, and more effectively achieve quality standards. These improvements not only help preserve vision but also generate economic value, as operational efficiencies can reduce service and litigation costs, complementing potential reductions in acquisition costs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.